Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study
Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 737-750
DOI: 10.3350/cmh.2025.1006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Heejoon Jang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, Korean Association for the Study of the Liver.
Abstract (Originalsprache)
Background/Aims: Patients with concurrent type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) face elevated cardiovascular risks. However, optimal oral antidiabetic drug (OAD) selection for this population remains unclear.
Methods
Using the Korean National Health Information Database, we conducted a target trial emulation comparing cardiovascular outcomes among patients with T2DM and MASLD (defined by fatty liver index ≥30) who initiated sodium-glucose cotransporter 2 (SGLT2) inhibitors, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, or sulfonylureas with metformin. The primary outcome was major adverse cardiovascular events (MACE), including cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke.
Results
Among 71,071 patients (331,726 person-years), SGLT2 inhibitor users experienced a significantly lower MACE risk compared to sulfonylurea users (adjusted subdistribution hazard ratio [aSHR], 0.44; 95% confidence interval [CI], 0.31–0.62). SGLT2 inhibitors also demonstrated a lower MACE risk compared to thiazolidinediones (aSHR, 0.61; 95% CI, 0.39–0.96) and DPP-4 inhibitors (aSHR, 0.59; 95% CI, 0.42–0.83). Cardiovascular mortality risk was notably reduced with SGLT2 inhibitors compared to sulfonylureas (aSHR, 0.13; 95% CI, 0.03–0.50), thiazolidinediones (aSHR, 0.19; 95% CI, 0.04–0.86), and DPP-4 inhibitors (aSHR, 0.22; 95% CI, 0.06–0.84). Mediation analysis revealed that MASLD regression accounted for 8.7% of the total cardiovascular benefit when comparing SGLT2 inhibitors to sulfonylureas.
Conclusions
In patients with concurrent T2DM and MASLD, SGLT2 inhibitors demonstrated better cardiovascular outcomes compared to other OADs. These findings suggest that SGLT2 inhibitors may be the preferred OAD choice for cardiovascular risk reduction in this high-risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea.
- Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Korea.
- Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Korea.
- Center for Reproduction, Metabolism and Molecular Medicine (CeRM), Department of Medicine (H7), Karolinska Institute, Huddinge, Stockholm, Sweden.
Förderung
- National Research Foundation of Korea
- Ministry of Education
- Korean Association for the Study of the Liver
- Seoul National University
Zitieren
APA
Jang, H., Kim, Y., Lim, Y. K., Lee, D. H., Joo, S. K., Koo, B. K., Kim, G. A., Lee, W., Romeo, S., Kim, W., & Innovative Target Exploration of NAFLD (ITEN) consortium (2026). Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study. Clinical and Molecular Hepatology, 32(2), 737-750. https://doi.org/10.3350/cmh.2025.1006
Vancouver
Jang H, Kim Y, Lim YK, Lee DH, Joo SK, Koo BK, et al. Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study. Clinical and Molecular Hepatology. 2026;32(2):737-750. doi:10.3350/cmh.2025.1006
BibTeX
@article{Jang2026,
author = {Jang, Heejoon and Kim, Yeonjin and Lim, Yoo Kyoung and Lee, Dong Hyeon and Joo, Sae Kyung and Koo, Bo Kyung and Kim, Gi-Ae and Lee, Woojoo and Romeo, Stefano and Kim, Won and Innovative Target Exploration of NAFLD (ITEN) consortium, Innovative Target Exploration of NAFLD (ITEN) consortium},
title = {Outcomes of oral antidiabetic drugs in metabolic dysfunction-associated steatotic liver disease: a nationwide target trial emulation study},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {2},
pages = {737--750},
doi = {10.3350/cmh.2025.1006}
}
EUVIMED